Melphalan in ultralow doses decreases the severity of experimental colitis in mice

[1]  A. Pukhalsky,et al.  Stimulatory and Protective Effects of Alkylating Agents Applied in Ultra-Low Concentrations , 2001, Pharmacology.

[2]  W. Falk,et al.  Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. , 2000, European cytokine network.

[3]  G. Hartmann,et al.  Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. , 1998, The Journal of pharmacology and experimental therapeutics.

[4]  H. Okamura,et al.  Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. , 1998, Scandinavian journal of gastroenterology.

[5]  G. Kollias,et al.  Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice , 1997, European journal of immunology.

[6]  K. Stecker,et al.  An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  W. Falk,et al.  Neutralization of tumour necrosis factor (TNF) but not of IL‐1 reduces inflammation in chronic dextran sulphate sodium‐induced colitis in mice , 1997, Clinical and experimental immunology.

[8]  C. Elson,et al.  Experimental models of inflammatory bowel disease. , 1995, Gastroenterology.

[9]  S. Khaidukov,et al.  Interleukin-2 receptor β chain as a possible target for low doses of mafosfamide , 1995, Mediators of inflammation.

[10]  C. Elson,et al.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. , 1994, Gastroenterology.

[11]  A. Pukhalsky,et al.  Immunosuppressive action of cyclophosphamide in mice: contribution of some factors to determination of strain differences. , 1993, International journal of immunopharmacology.